Wang J, Ding L L, Yan Y F, Chen Y S, Xu Y Y, Lu L L, Gong H J, Zhu J
Department of Etiology, Affiliated Qidong Hospital of Nantong University, Qidong Liver Cancer Institute, Qidong 226200, China.
Department of Oncology, Qidong People's Hospital, Qidong 226200, China.
Zhonghua Zhong Liu Za Zhi. 2025 Jun 23;47(6):477-484. doi: 10.3760/cma.j.cn112152-20241009-00436.
To analyze pancreatic cancer incidence and mortality data in China and worldwide and to provide data for pancreatic cancer prevention and control efforts. Data of pancreatic cancer incidence and mortality rates, along with historical and predictive data, were obtained from the GLOBOCAN 2022 database. Epidemiological characteristics of pancreatic cancer was analyzed by region, sex, age and Human Development Index (HDI). Spearman's correlation coefficient test was used to assess the relationship between HDI and age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR). In 2022, the global number of new cases and deaths of pancreatic cancer will be 511 thousand and 467 thousand, respectively, with an ASIR and ASMR of 4.7/10 and 4.2/10, respectively. North America and Europe had the highest pancreatic cancer incidence and mortality rates of 8.5/10 and 7.3/10, respectively. Global ASIR and ASMR in men were both 1.4 times higher than those in women. HDI levels were positively correlated with ASIR (=0.79, ＜0.001) and ASMR (=0.78, ＜0.001) of pancreatic cancer in all regions. The number of pancreatic cancer cases and deaths in China were 119 thousand and 106 thousand, respectively, while the ASIR and ASMR of pancreatic cancer were 4.4/10 and 3.9/10, respectively. Both ASIR and ASMR in men were both 1.5 times higher than those in women in China. The number of pancreatic cancer incidence and death cases in China in 2050 is predicted to be 216 thousand and 204 thousand cases, with an increase of 81.5% and 92.5% compared with 2022, respectively. The disease burden of pancreatic cancer varies significantly among different regions, genders and ages. Pancreatic cancer incidence and mortality are positively correlated with HDI. The incidence and mortality rates of pancreatic cancer in China are close to the global average, but the number of new cases and deaths is high. Prevention and control should be strengthened to improve the survival of pancreatic cancer patients.
分析中国及全球胰腺癌的发病率和死亡率数据，为胰腺癌防控工作提供数据支持。胰腺癌发病率和死亡率数据以及历史和预测数据均来自GLOBOCAN 2022数据库。按地区、性别、年龄和人类发展指数（HDI）分析胰腺癌的流行病学特征。采用Spearman相关系数检验评估HDI与年龄标准化发病率（ASIR）和年龄标准化死亡率（ASMR）之间的关系。2022年，全球胰腺癌新发病例和死亡病例数分别为51.1万和46.7万，ASIR和ASMR分别为4.7/10万和4.2/10万。北美和欧洲的胰腺癌发病率和死亡率最高，分别为8.5/10万和7.3/10万。全球男性的ASIR和ASMR均为女性的1.4倍。所有地区的HDI水平与胰腺癌的ASIR（=0.79，＜0.001）和ASMR（=0.78，＜0.001）均呈正相关。中国胰腺癌病例数和死亡数分别为11.9万和10.6万，而胰腺癌的ASIR和ASMR分别为4.4/10万和3.9/10万。中国男性的ASIR和ASMR均为女性的1.5倍。预计2050年中国胰腺癌发病和死亡病例数分别为21.6万和20.4万例，与2022年相比分别增加81.5%和92.5%。胰腺癌的疾病负担在不同地区、性别和年龄之间存在显著差异。胰腺癌发病率和死亡率与HDI呈正相关。中国胰腺癌的发病率和死亡率接近全球平均水平，但新发病例和死亡数较高。应加强防控以提高胰腺癌患者的生存率。
